Cervical Cancer Clinical Trial
Official title:
A Prospective Study of Dynamic Monitoring Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy
Perspectives:
To analyse if the change of specific immune response will correlate with clinical effect of
advanced cervix cancer after radio-chemotherapy.
To evaluate the specific immune response throughout monitor the change of the programmed
death-1(PD-1) in CD8 T cell and CD4 T cell and Treg cell in blood at baseline, before first
brachytherapy and before the last brachytherapy in the advanced Cervix Cancer patients.
To use immunohistochemistry (IHC) technique to monitor the change of programmed death-ligand
1 (PD-L1),CD68,CD8,CD4,PD1 and Treg expression in biopsy at baseline, before first
brachytherapy and before the last brachytherapy in the advanced Cervix Cancer patients.
To detect the change of T cell receptor(TCR) repertoire and Tumor mutation burden (TMB) at
baseline, before first brachytherapy and before the last brachytherapy in the advanced Cervix
Cancer patients.
Cervical cancer is the fourth most common cancer among women worldwide. At present, patients
with cervical cancer are treated with radical hysterectomy and pelvic lymphadenectomy or
chemoradiation. To improve the prognosis of cervical cancer patients, novel immunotherapeutic
strategies need to be developed. Now there are some clinical phase I/II trials ongoing to
assess the effects of ipilimumab, pembrolizumab and nivolumab in advanced cervical cancer,but
information on the clinical significance of PD-L1 expression in cervical cancer is largely
lacking.In this study, the investigator's primary objective:
To analyse if the change of specific immune response will correlate with clinical effect of
advanced cervix cancer after radio-chemotherapy.
To evaluate the specific immune response throughout monitor the change of PD-1 in CD8 T cell
and CD4 T cell and Treg cell in blood at baseline, before first brachytherapy and before the
last brachytherapy in the advanced Cervix Cancer patients.
To use IHC technique to monitor the change of PD-L1, CD68,CD8,CD4,PD1 and Treg expression in
biopsy at baseline, before first brachytherapy and before the last brachytherapy in the
advanced Cervix Cancer patients.
To detect the change of TCR repertoire and TMB at baseline, before first brachytherapy and
before the last brachytherapy in the advanced Cervix Cancer patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
| Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
| Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
| Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
| Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
| Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
| Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
| Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
| Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |